Fingolimod for relapsing-remitting multiple sclerosis (Q24185882)

2

0 references

Loredana La Mantia

1

0 references

author name string

Belal Firwana

3

0 references

Ilaria Pacchetti

4

0 references

Roberto Palumbo

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 April 2016

0 references

published in

0 references

cites work

Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Fingolimod treatment in multiple sclerosis leads to increased macular volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Drugs in development for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Clinical pharmacokinetics of fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Assessment of the SF-36 version 2 in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

The changing demographic pattern of multiple sclerosis epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Epidemiology of multiple sclerosis in Europe: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Defining the clinical course of multiple sclerosis: the 2013 revisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Assessing risks of multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Fingolimod for relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: no

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

Risk stratification and patient counseling for natalizumab in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F,

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009371.PUB2

7 January 2021